News

Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference

January 2019

Ability Pharmaceuticals, SL announced today that Carles Domènech, PhD, Chief Executive Officer and co-Founder, will be attending the 4th BIOMED EVENT® by INVEST SECURITIES on Tuesday, January 22, 2019 in Paris. The conference is highly transactional, bringing together an exciting cross-section of small-cap venture-funded companies with leading investors, pharmas, and investment service providers.

Besides that, Hector Perez-Montoyo, PhD,  Biological Research Director, is attending the 2019 Cholangiocarcinoma Foundation Annual Conference from January 30th to February 2nd, 2019 in Salt Lake City, Utah, USA. The Cholangiocarcinoma Foundation's annual program seeks to develop sustainable participation of the medical and research communities in the field of cholangiocarcinoma. 
 

LATEST NEWS

09.06.2020

News

AbilityPharma publishes full characterization of mechanism of action of ABTL0812, a Phase II clinical inducer of cytotoxic autophagy in cancer cells, in Autophagy journal + info
25.03.2020

News

AbilityPharma awarded €5 million from the Horizon Europe EIC Accelerator Pilot Program to conduct a Phase 2b clinical trial with ABTL0812 in patients with advanced pancreatic cancer + info
12.09.2019

News

AbilityPharma rises € 3.5 million in a financing round to complete the current oncologic phase 2 clinical trial and license ABTL0812 to an international pharmaceutical company + info
31.05.2019

News

Ability Pharmaceuticals Announces the Presentation of the First Results of ABTL0812 as First Line in Patients with Endometrial or Lung Cancer at 2019 ASCO Annual Meeting + info
04.02.2019

News

Ability Pharmaceuticals Announces the Approval in China of a Clinical Study in Pancreatic Cancer with ABTL0812 + info
30.01.2019

News

Ability Pharmaceuticals is attending the BIOMED EVENT® by INVEST SECURITIES and the Cholangiocarcinoma Foundation Annual Conference + info
05.12.2018

News

AbilityPharma ha superado el millón de euros en la ronda de crowdfunding que abrió el pasado mes de septiembre + info
07.11.2018

News

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer + info
19.09.2018

News

Ability Pharmaceuticals anuncia la inclusión del primer paciente en el estudio clínico de la fase 2 de ABTL0812 en Francia + info
© 2012 Ability Pharma / All Rights Reserved / Legal Notice / Privacy Police
NEORG